India, Oct. 20 -- Tuesday, Creative Medical Technology Holdings (CELZ) said its investigational Ultrasome platform showed a 93% patient response rate and an approximately 65% reduction in average pain scores in a knee osteoarthritis pilot study.
Ultrasome is a cell-free regenerative medicine platform using extracellular-vesicle-rich secretome material. It is not FDA-approved for knee osteoarthritis or other indications.
The open-label, single-arm study followed 30 patients with osteoarthritis in both knees for six months. It had no randomized or sham-controlled comparator.
Twenty-eight patients met study-defined criteria for clinical improvement. The approximately 65% decline reflected the reduction in the group's average pain score, rat...